<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003654</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066746</org_study_id>
    <secondary_id>FRE-FNCLCC-96008</secondary_id>
    <secondary_id>EU-98055</secondary_id>
    <nct_id>NCT00003654</nct_id>
  </id_info>
  <brief_title>Diagnostic Study to Identify Sentinel Lymph Nodes in Women With Stage I or Stage II Breast Cancer</brief_title>
  <official_title>Diagnostic Study of Patent Blue V Dye to Identify Sentinel Lymph Nodes in Patients With Stage I or IIA Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures, such as blue dye or imaging to identify sentinel lymph&#xD;
      nodes, may improve the ability to detect the extent of disease and help plan effective&#xD;
      surgery for removing breast tumors.&#xD;
&#xD;
      PURPOSE: Diagnostic trial to study the effectiveness of blue dye and an imaging procedure to&#xD;
      identify the sentinel lymph node under the arm in women with stage I or stage II breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine whether the concept of a sentinel lymph node within the axillary&#xD;
      nodal basin is valid in staging breast cancer. II. Determine the sensitivity of combined&#xD;
      methods of identification of sentinel lymph nodes by patent blue V dye and gamma probe&#xD;
      detection in these women.&#xD;
&#xD;
      OUTLINE: Patients receive patent blue V dye injection peritumorally prior to surgery.&#xD;
      Preoperative lymphoscintigraphy is performed using technetium Tc 99 sulfur rhenium colloid&#xD;
      injected around the tumor associated with intraoperative gamma probe detection. Nonpalpable&#xD;
      tumors receive a localized injection using stereotactic injection techniques. Patients then&#xD;
      undergo standard axillary (level I and II) lymph node dissection.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study within 1 year.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">September 1997</start_date>
  <completion_date type="Actual">January 2000</completion_date>
  <primary_completion_date type="Actual">January 2000</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Diagnostic</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>patent blue V dye</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>lymphangiography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radionuclide imaging</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>sentinel lymph node biopsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>technetium Tc 99m sulfur colloid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically or cytologically proven stage I or IIA invasive&#xD;
        breast cancer T0, T1, or T2 (no greater than 3 cm), N0 Noninflammatory Nonmetastatic No&#xD;
        ductal carcinoma in situ Eligible for breast-conserving surgery Hormone receptor status:&#xD;
        Positive or negative&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: Any age Sex: Female Menopausal status: Pre- and&#xD;
        postmenopausal Performance status: Not specified Life expectancy: Not specified&#xD;
        Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Not&#xD;
        pregnant No allergy or sensitivity to radiopharmaceuticals or patent blue V dye&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: No&#xD;
        prior neoadjuvant chemotherapy Endocrine therapy: No prior endocrine therapy Radiotherapy:&#xD;
        No prior neoadjuvant radiotherapy Surgery: No prior breast surgical biopsy or axillary&#xD;
        surgery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>0 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Francois Rodier, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Paul Strauss</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67085</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>August 25, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2004</study_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Technetium Tc 99m Sulfur Colloid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

